Zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) - The Phase 3 ALPINE Trial

 SLIDE KIT   13   07/2021

ALPINE is a global, randomized phase 3 study comparing zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

In an interim analysis zanubrutinib was shown to have a superior response rate and a lower rate of atrial fibrillation/flutter as compared with ibrutinib. These data support that more selective BTK inhibition results in improved efficacy and safety outcomes.


Rate this resource

Nice to see you!

For newest details on our EHA materials in a personal video meeting, please click here!